Eli Lilly's Mounjaro met goal of cardiovascular benefit in head-to-head trial with Trulicity

Key Concepts

• Mounjaro: Eli Lilly's diabetes drug.
• Trulicity: Eli Lilly's older GLP-1 drug for diabetes.
• GLP-1: Glucagon-like peptide-1 receptor agonists, a class of drugs used to treat type 2 diabetes.
• Cardiovascular Events: Events such as stroke and heart attack.
• Non-inferiority: Showing that a treatment is not worse than another.
• Ozempic Face: The phenomenon of facial skin sagging due to rapid weight loss from drugs like Ozempic.

Mounjaro Trial Results and Market Reaction

• Trial Objective: Eli Lilly conducted a phase three trial to assess Mounjaro's impact on heart disease risk in type 2 diabetes patients. The trial was designed to show Mounjaro was no worse than Trulicity in terms of cardiovascular outcomes (non-inferiority).
• Trial Results: Mounjaro met the primary goal, demonstrating an 8% lower rate of cardiovascular events compared to Trulicity and a 16% reduction in death from any cause.
• Market Disappointment: Despite meeting the non-inferiority goal, the market reacted negatively (Lilly's stock down about 4%). This is because investors and analysts had higher expectations, hoping for a significantly greater than 10% reduction in cardiovascular events.
• Doctor's Perspective: One doctor expressed concern that the results might not be compelling enough to convince insurers to provide broad coverage for Mounjaro, especially in the US, since it wasn't significantly better than Trulicity.
• Lilly's Perspective: Lilly views the data as positive, strengthening the case for Mounjaro with insurers, particularly in international markets where the drug is being launched.
• Future Data: Full trial results will be presented at a medical meeting in September, which may provide more clarity and influence market sentiment.

Coverage and Insurer Considerations

• Existing GLP-1 Data: Other GLP-1 drugs have already demonstrated heart benefits, so Mounjaro's positive results in this area were not entirely surprising to doctors.
• Coverage Concerns: The concern is that insurers may limit coverage of Mounjaro if it's not significantly superior to Trulicity, especially given the cost of newer medications.

Ozempic Face and the Plastic Surgery Boom

• Ozempic Face Phenomenon: Rapid weight loss from drugs like Ozempic is leading to increased demand for plastic surgery to address loose skin, particularly in the face.
• Investment Opportunities: The discussion briefly touches on potential investment opportunities related to this trend, such as Botox or AbbVie, but no specific recommendations are made.
• Personal Anecdotes: There's a brief exchange about personal experiences and observations related to Ozempic face.

Synthesis/Conclusion

The Mounjaro trial results, while positive in demonstrating non-inferiority to Trulicity, fell short of market expectations for a significant improvement in cardiovascular outcomes. This has led to concerns about insurer coverage and a negative market reaction. The full data presentation in September will be crucial. Separately, the rise of "Ozempic face" is creating a boom in the plastic surgery industry, highlighting an unexpected consequence of weight loss drugs.